文献速递心外重症与机械循环支持

术前体外膜氧合治疗对心室辅助装置置入术后结局的影响:基于STS Pedimacs数据库的分析

Effect of preoperative extracorporeal membrane oxygenation therapy on postventricular assist device outcomes: an analysis of the STS Pedimacs database.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

该研究基于STS Pedimacs注册数据库,比较了541例INTERMACS 1和2级儿科患者中,VAD术前接受ECMO支持(150例)与未接受ECMO支持(391例)的术后结局。结果显示术前ECMO支持与术后死亡率升高无独立关联(P=0.12),但INTERMACS 1级、低体重、肝功能障碍、肾功能衰竭及使用体外连续流或经皮辅助装置与更高的术后死亡率相关。

要点

  • 术前ECMO支持不是VAD术后死亡率升高的独立危险因素(P=0.12)。
  • INTERMACS 1级、低体重、肝功能障碍、肾功能衰竭与术后死亡率升高相关。
  • 体外连续流和经皮辅助装置与更高的术后死亡率相关。

核心结论

  • INTERMACS 1级、低体重、肝功能障碍、肾功能衰竭以及使用体外连续流或经皮辅助装置与更高的术后死亡率相关;术前ECMO治疗与术后死亡率升高无独立关联(P=0.12)。

研究设计与样本

  • 基于STS Pedimacs注册数据库的分析,纳入541例INTERMACS 1和2级儿科患者,其中391例接受直接VAD置入,150例在VAD治疗前使用了ECMO。

主要发现

  • 与未使用ECMO组相比,术前ECMO组年龄更小(P<0.0001)且休克更常见(P<0.0001),1、6、12个月生存率更低(P<0.0001)。
  • 未使用ECMO组感染豁免率更高(P=0.03),卒中豁免率相似(P=0.7)。
  • 体外连续流装置在两组中生存率均较差(P=0.4);植入式连续流装置(P<0.0001)和体外搏动式装置(P=0.007)在直接VAD组生存率更好。
  • INTERMACS 1级患者两组1、6、12个月生存率相似(P=0.1)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Extracorporeal membrane oxygenation (ECMO) support prior to ventricular assist device (VAD) therapy is frequently used for stabilizing INTERMACS 1 and 2 paediatric patients. Data regarding outcomes with this strategy is limited. METHODS: Patient characteristics and outcomes post-VAD therapy with and without preop ECMO support were compared. Survival and risk factor analysis was performed for all patients and INTERMACS profile 1 subgroup. RESULTS: Of 541 INTERMACS 1 and 2 patients enrolled in Paediatric Interagency Registry for Mechanical Circulatory Support registry, 391 received primary VAD implantation and ECMO prior to VAD therapy was utilized in 150 patients. Younger age (P < 0.0001) and shock (P < 0.0001) were more common in group 2, with lower survival at 1, 6 and 12 months compared to group 1 (P < 0.0001). Freedom from infection (P = 0.03) was higher in group 1. Freedom from stroke (P = 0.7) was similar. Paracorporeal continuous flow devices led to poor survival in both groups 1 and 2 (P = 0.4). Implantable continuous flow (P < 0.0001) and paracorporeal pulsatile devices (P = 0.007) had better survival in primary VAD group. INTERMACS profile 1, lower weight, hepatic dysfunction, renal failure, paracorporeal continuous and percutaneous devices were associated with higher mortality. Preop ECMO therapy was not associated with higher mortality (P = 0.12). Survival of INTERMACS profile 1 patient was similar at 1, 6 and 12 months in both groups (P = 0.1). CONCLUSIONS: INTERMACS profile 1, lower weight, hepatic dysfunction, renal failure and use of paracorporeal continuous flow or percutaneous assist devices are associated with a higher postoperative mortality. Preop ECMO therapy however is not independently associated with higher postop mortality.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Peer SM, Koehl DA, Cantor RS, et al. Effect of preoperative extracorporeal membrane oxygenation therapy on postventricular assist device outcomes: an analysis of the STS Pedimacs database. Eur J Cardiothorac Surg. 2022. PMID: 36227147. doi:10.1093/ejcts/ezac485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。